Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elicio Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company focused on cancer immunotherapies. Its disclosures cover common stock registered on The Nasdaq Capital Market, emerging growth company reporting status, operating and financial results, corporate updates, and material-event reports.
Recent filings also address capital-structure matters, including an at-the-market equity program tied to a Form S-3 registration statement, as well as Regulation FD and other event disclosures for ELI-002, AMPLIFY-7P, AMPLIFY-201, mKRAS-specific T cell response data, scientific publications, governance matters, shareholder voting topics, and risk-related clinical and regulatory updates.
Elicio Therapeutics ownership update: Knoll Capital Management, Fred Knoll and Gakasa Holdings amended their Schedule 13G/A to report beneficial ownership of 1,211,957 shares of Common Stock, representing 5.3% of the class. The filing shows shared voting and shared dispositive power for the same amount.
Elicio Therapeutics, Inc. is offering 4,380,313 shares of common stock in a registered offering priced at $3.43 per share (aggregate offering price $15,024,473.59). Delivery is expected on or about July 6, 2026.
The company expects net proceeds of approximately $13.6 million to fund a planned Phase 1 study of ELI-002 7P in metastatic mKRAS PDAC, advance its pipeline and platform, and for working capital and general corporate purposes. The prospectus supplement discloses AMPLIFY-7P Phase 2 topline results which did not meet the prespecified primary DFS endpoint in the intent-to-treat population, but post-hoc analyses indicated early DFS benefit and a stronger effect in the R0 resected subgroup; a Phase 3 strategy focused on R0 patients is planned, subject to financing.
Elicio Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 4,380,313 shares of common stock at $3.43 per share, for aggregate gross proceeds of about $15 million before fees and expenses. The offering is being conducted under Elicio’s effective Form S-3 shelf registration statement and is expected to close on or about July 6, 2026, subject to customary conditions.
The company agreed to a 30-day restriction on issuing additional common stock or equivalents after closing. Elicio intends to use net proceeds, together with existing cash and investments, primarily to fund planned Phase 1 development of ELI-002 7P in metastatic pancreatic ductal adenocarcinoma, its broader pipeline and platform, and for working capital and general corporate purposes.
Elicio Therapeutics, Inc. furnished an investor presentation after hosting a virtual key opinion leader event on the path forward for its cancer vaccine candidate ELI-002 7P in metastatic KRAS-mutant pancreatic ductal adenocarcinoma. Clinicians discussed historical data showing complete responses are rare in metastatic pancreatic cancer, even with modern chemotherapy and immunotherapy combinations.
The presentation highlighted three patients previously treated with ELI-002 7P who later received nivolumab-based therapy and achieved complete radiographic, metabolic and biomarker responses, with two maintaining responses for at least nine months. Elicio outlined a planned, funding-dependent Phase 1 study combining ELI-002 7P with checkpoint inhibition and chemotherapy in recurrent and treatment‑naïve metastatic disease to generate early clinical and immune-response signals within 3–6 months of study start.
Elicio Therapeutics, Inc. reported preliminary clinical observations in metastatic mutant KRAS pancreatic cancer after treatment with its investigational immunotherapy ELI-002 7P. Three patients who had progressed on ELI-002 7P in the Phase 2 AMPLIFY-7P study later received nivolumab-based therapy and achieved 100% confirmed complete radiographic and complete metabolic responses, with concurrent normalization of CA19-9 tumor marker levels and persistent mKRAS-specific T cell responses.
The company notes that complete responses in metastatic pancreatic cancer have been reported at roughly 0%–8% in published studies, making these three complete, durable responses in microsatellite stable / mismatch repair proficient patients notable. Elicio plans, subject to funding, to initiate a Phase 1 study of ELI-002 7P combined with standard chemotherapy and an anti–PD-1 inhibitor in first-line metastatic pancreatic ductal adenocarcinoma, and will host a virtual key opinion leader event on June 24, 2026 to further discuss the findings.
Elicio Therapeutics reported detailed results from its randomized Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer. The study’s primary endpoint of disease-free survival in the intent-to-treat population was not met, but early landmark analyses showed about a 14% absolute DFS benefit during active treatment at 3 and 6 months, with curve separation through 9 months.
Post-hoc analyses highlighted a stronger effect in completely resected R0 patients, where ELI-002 7P achieved a DFS hazard ratio of 0.65 and median DFS of 23.8 months versus 12.8 months for observation. Higher-risk R1 resections were more common in the ELI-002 arm, which the company believes dampened overall results. mKRAS-specific T cell responses strongly correlated with improved DFS, and safety was favorable with no treatment-related discontinuations or deaths. Elicio plans a Phase 3 trial focused on R0 patients with extended dosing and expects current cash to fund operations into the fourth quarter of 2026, while evaluating additional financing and partnering options.
Elicio Therapeutics reported a net loss of $11.8 million for the three months ended March 31 2026, as it continues developing its AMP-based cancer immunotherapies. Operating expenses were $10.6 million, led by $6.8 million in research and development and $3.8 million in general and administrative costs.
Cash and cash equivalents were $14.9 million with total assets of $22.7 million and stockholders’ deficit of $1.4 million as of March 31 2026. Management discloses substantial doubt about the company’s ability to continue as a going concern, estimating its current cash runway extends into the fourth quarter of 2026.
To bolster liquidity, Elicio raised net proceeds of about $8.0 million in the quarter through at-the-market equity programs and carries a $10.0 million Senior Secured Promissory Note bearing interest of up to 12.5%. The company expects continued losses as it advances its Phase 2 ELI-002 7P program and preclinical pipeline.
Elicio Therapeutics reported first quarter 2026 results and highlighted progress in its Phase 2 AMPLIFY-7P trial of ELI-002 7P in KRAS-driven pancreatic cancer. The primary disease-free survival analysis is expected mid-year 2026, and fewer disease progressions and deaths than projected have been observed so far.
R&D expenses were $6.8 million versus $7.8 million a year earlier, while G&A expenses rose to $3.8 million from $3.0 million. Net loss was $11.8 million compared to $11.2 million, with net loss per share improving to $0.65 from $0.87.
Cash and cash equivalents were $14.9 million at March 31, 2026, down from $18.6 million at December 31, 2025. The company raised approximately $13.0 million through its at-the-market program in Q1 and early Q2 2026 and now expects its cash runway to extend into Q4 2026, beyond the anticipated AMPLIFY-7P DFS readout.
Elicio Therapeutics, Inc. files Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive compensation, corporate governance and security ownership that was omitted from the original 10-K.
The filing reports an aggregate market value of common stock held by non-affiliates of approximately $81.8 million based on the Nasdaq Capital Market closing price on June 30, 2025. Shares of common stock outstanding were 18,704,798 as of April 9, 2026.